THERAPY DOSSIER · th-b479cd3aa5b5

Bixin (from annatto seeds)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 3

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05236205 ↗PHASE2unknown

aPDT with Bixa orellana (annatto) extract 20% as adjunct for deep caries lesions

Caries

Enrolment: 160 · Results not recorded

NCT03346460 ↗PHASE2unknown

Photodynamic therapy with urucum (annatto) and LED in reduction of halitosis

Halitosis

Enrolment: 45 · Results not recorded

NCT05590897 ↗PHASE1/PHASE2completed

Photodynamic therapy with annatto and LED for halitosis in mouth-breathing children

Halitosis

Enrolment: 52 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24372269 ↗2013Reported benefit

Bixin action in the healing process of rats mouth wounds.

RatWoundWistarMalen = 64 rats in 8 groups (4 saline and 4 bixin groups)From the start of treatment after ulcer induction

Model: Ulcer induced with a 0.5 cm punch in the middle of the dorsum of the tongue

Bixin reduced mean neutrophil numbers at all time points (p=0.000), increased total collagen area by 2 days (4139.60 plus or minus 3047.51 versus 1564.81 plus or minus 918.47, p=0.044) and mature collagen deposition at 14 days (5802.40 plus or minus 3578.18 versus 1737.26 plus or minus 1439.97, p=0…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…